BLOOD GLUCOSE MONITORING: CLINICAL NEED AND TECHNOLOGY
DAVID C KLONOFF, MD

Medical Director
Diabetes Research Institute of
Mills-Peninsula Health Services
San Mateo, California

Clinical Professor of Medicine,
University of California at San Francisco
Mills-Peninsula Health Center
San Mateo, California
SMBG - AN ESTABLISHED AND EVOLVING INTERVENTION TO IMPROVE OUTCOMES

CURRENT STATUS

- Safety to pts/non-pts is under scrutiny
- Accuracy requirements are in flux and industry must now improve accuracy
- Clinical indications are established for insulin Rx but controversial in NIT T2
- New barriers & opportunities ensure that SMBG has an unknown future
SMBG - AN ESTABLISHED AND EVOLVING INTERVENTION TO IMPROVE OUTCOMES

CURRENT STATUS

- Safety to pts/non-pts is under scrutiny
- Accuracy requirements are in flux and industry must now improve accuracy
- Clinical indications are established for insulin Rx but controversial in NIT T2
- New barriers & opportunities ensure that SMBG has an unknown future
FUTURE DIRECTIONS IN BLOOD GLUCOSE MONITORING

- Technology
- Safety
- Accuracy
- Clinical Indications
- Barriers and Opportunities
Glucose

Oxidizing Enzyme

Electrons

Electric Current

Electrons

Color Change

Amperometric and Colorimetric Glucose Sensors
FOUR GENERATIONS OF GLUCOSE BIOSENSORS

FIRST GENERATION BIOSENSOR

Glucose $\rightarrow$ FAD $\rightarrow$ Gluconic Acid $\rightarrow$ Glucose

H$_2$O$_2$ $\rightarrow$ O$_2$ $\rightarrow$ Gluconic Acid $\rightarrow$ FADH$_2$

SECOND GENERATION BIOSENSOR

Glucose $\rightarrow$ FAD $\rightarrow$ Gluconic Acid $\rightarrow$ Glucose

FAD$\rightarrow$Med$_{\text{RED}}$$\rightarrow$ Med$_{\text{OX}}$$\rightarrow$FADH$_2$

THIRD GENERATION ENZYMATIC BIOSENSOR

Glucose $\rightarrow$ FAD$\rightarrow$ENZYME$\rightarrow$Gluconic Acid $\rightarrow$ FADH$_2$

FOURTH GENERATION NON-ENZYMATIC BIOSENSOR

Glucose $\rightarrow$ CATALYSIS WITHOUT AN ENZYME

Gluconic Acid $\rightarrow$ + 2H$^+$ + 2 e$^-$
FOUR GENERATIONS OF GLUCOSE BIOSENSORS

FIRST GENERATION BIOSENSOR

Glucose $\xrightarrow{\text{GLUCOSE OXIDASE}}$ FAD $\xrightarrow{\text{GLUCOSE OXIDASE}}$ H$_2$O$_2$ $\xrightarrow{\text{ELECTRODE}}$ Gluconic Acid $\xrightarrow{\text{ELECTRODE}}$ FADH$_2$

REQUIRES OXYGEN

SECOND GENERATION BIOSENSOR

Glucose $\xrightarrow{\text{GLUCOSE DEHYDROGENASE}}$ FAD $\xrightarrow{\text{ELECTRODE}}$ Med$_{\text{RED}}$ $\xrightarrow{\text{ELECTRODE}}$ FADH$_2$ $\xrightarrow{\text{Med}_{\text{OX}}} + 2H^+ + 2e^-$

REQUIRES MEDIATOR

THIRD GENERATION ENZYMATIC BIOSENSOR

Glucose $\xrightarrow{\text{ENZYME}}$ FAD $\xrightarrow{2H^+ + 2e^-} FADH_2$ $\xrightarrow{\text{ELECTRODE}}$ Gluconic Acid $\xrightarrow{\text{ELECTRODE}}$ FADH$_2$

REQUIRES SPECIAL ENZYME

FOURTH GENERATION NON-ENZYMATIC BIOSENSOR

Glucose $\xrightarrow{\text{ELECTRODE}}$ Gluconic Acid $\xrightarrow{\text{ELECTRODE}} + 2H^+ + 2e^-$

REQUIRES SPECIAL ELECTRODE

CATALYSIS WITHOUT AN ENZYME
SAFETY
SAFETY OF SMBG: WHAT ARE THE RISKS?

- Transmission of bloodborne viral pathogens from patient to patient
- Community exposure to sharps and other medical waste
- Finger trauma due to lancing
SAFETY OF SMBG: WHAT ARE THE RISKS?

- Transmission of bloodborne viral pathogens from patient to patient
- Community exposure to sharps and other medical waste
- Finger trauma due to lancing
Eliminating the Blood: Ongoing Outbreaks of Hepatitis B Virus Infection and the Need for Innovative Glucose Monitoring Technologies

Nicola D. Thompson, Ph.D., M.S.,1 and Joseph F. Perz, Dr.P.H., M.A.2

Abstract

Background:
As part of routine diabetes care, capillary blood is typically sampled using a finger-stick device and then tested using a handheld blood glucose meter. In settings where multiple persons require assistance with blood glucose monitoring, opportunities for bloodborne pathogen transmission may exist.

Methods:
Reports of hepatitis B virus (HBV) infection outbreaks in the United States that have been attributed to blood glucose monitoring practices were reviewed and summarized.

Results:
Since 1990, state and local health departments investigated 15 HBV infection outbreaks, 15 (63%) in the past 10 years, that were associated with the improper use of blood glucose monitoring equipment. At least 147 persons acquired HBV infection during these outbreaks, 6 (41%) of whom died from complications of acute HBV infection. Outbreaks appear to have become more frequent in the past decade, primarily affecting long-term care residents with diabetes. Each outbreak was attributed to glucose monitoring practices that exposed HBV-susceptible persons to blood-contaminated equipment that was previously used on HBV-infected persons. The predominant unsafe practices were the use of spring-loaded finger-stick devices on multiple persons and the sharing of blood glucose testing meters without cleaning and disinfection between uses.

Conclusion:
Hepatitis B virus infection outbreaks associated with blood glucose monitoring have occurred with increasing regularity in the United States and may represent a growing but under-recognized problem. Advances in technology, such as the development of blood glucose testing meters that can withstand frequent disinfection and noninvasive glucose monitoring methods, will likely prove useful in improving patient safety.


Author Affiliations: Epidemiology and Surveillance Branch, Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia; and Prevention and Response Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, Georgia

Abbreviations: (CDC) Centers for Disease Control and Prevention, (HBV) hepatitis B virus, (HCV) hepatitis C virus, (HIV) human immuno-deficiency virus, (LTIC) long-term care

Keywords: bloodborne virus, blood glucose monitoring, diabetes, hepatitis B virus, prevention, transmission

Corresponding Author: Nicola D. Thompson, Ph.D., M.S., 1600 Clifton Road, MS G-37, Atlanta, GA 30333; email address: ndthompson@dcoe.cdc.gov
TYPES OF UNSAFE BLOOD GLUCOSE MONITORING PRACTICES ASSOCIATED WITH HEPATITIS B

- Vectors of transmission were typically spring loaded lancets for individual use
- No outbreaks were due to reused lancets
- Disposable endcaps for lancets were reused or stored with unused endcaps
- In all cases BG meters were shared and not cleaned between measurements

David C. Klonoff, M.D., FACP, and Joseph F. Perz, Dr.PH.

Abstract

T

he term “assisted monitoring of blood glucose” (AMBG) is a new paradigm in blood glucose testing and is introduced in this editorial. Assisted monitoring of blood glucose is similar to self-monitoring of blood glucose (SMBG), but unlike SMBG for which patients perform the monitoring, AMBG is performed for a patient with diabetes by a health care provider or other caregiver. Assisted and self-monitoring both have long traditions in practice, but it is important that AMBG be recognized more broadly as a distinct concept in order to address safety concerns. In many instances, the equipment and personnel that are appropriate for an individual performing SMBG are not appropriate in an AMBG setting. The primary reason for this is the ever-present risk of transmitting bloodborne viruses between individuals who are having capillary blood samples clamped and tested. This risk is heightened when finger-prick lancet devices, blood glucose meters, or other equipment are used for multiple patients.

Self-Monitoring of Blood Glucose

The practice of SMBG is a basic intervention for all patients with diabetes and generally is considered very safe. Patients with diabetes risk themselves routinely with a lancet to obtain a blood sample with which to perform SMBG. Basic diabetes education programs teach and promote this practice, and have emphasized safe disposal of sharp paraphernalia as a means to avoid contaminating others with blood waste. To transmit a bloodborne virus, a susceptible patient must come in contact with blood from another person. If a diabetes patient never shares equipment, supplies, or insulin with anyone else and safe waste disposal practices are followed, then there should be no risk of transmission from one person to another.

Most blood glucose monitoring equipment has been designed for sale/use in the context of personal use for SMBG. Device design emphasizes features such as comfort, convenience, and portability. However, an important, growing, but inadequately studied setting for blood glucose monitoring is the environment where patients are not monitoring themselves, but rather receiving assistance with their monitoring from a caregiver or health care provider (i.e., AMBG). Types of settings for assisted living facilities (ALFs) where patients receive assistance with blood glucose monitoring are shown in Table 1.

Author Affiliations: Mills-Peninsula Health Services, San Mateo, California, and Centers for Disease Control and Prevention, Atlanta, Georgia.

Abbreviations: (ALF) assisted living facility, (AMBG) assisted monitoring of blood glucose, (CDC) Centers for Disease Control and Prevention, (HIV) human immunodeficiency virus (HIV), (SMBG) self-monitoring of blood glucose.

Keywords: assisted monitoring of blood glucose, blood-borne infection, diabetes, glucose, hepatitis, monitor, self-monitoring of blood glucose.

Corresponding Author: David C. Klonoff, M.D., FACP, Mills-Peninsula Health Services, 100 South San Mateo Dr., Room 415, San Mateo, CA 94402; email address: dklonoff@msn.com.


David C. Klonoff, M.D., FACP, and Joseph F. Perz, Dr.P.H.

A New Paradigm

The term "assisted monitoring of blood glucose" has often been misconstrued as a blood sample with which to test a patient's glucose levels. This can lead to a new paradigm in blood glucose monitoring. In recent years, various programs teach patients how to use glucose meters at home to test their blood glucose levels. However, many patients may not be able to use these devices properly, especially those with poor hand-eye coordination. As a result, there is a need for more education on how to use these devices properly.

Self-Monitoring of Blood Glucose

The practice of SMBG is a basic intervention for all patients with diabetes and is generally considered very safe. Patients with diabetes who use SMBG can easily monitor their glucose levels and adjust their treatment accordingly. However, in many cases, SMBG is not being used as effectively as it could be. This is largely due to inadequate education on how to use SMBG properly. Inadequate education can lead to incorrect readings and potentially dangerous situations.

Author Affiliations: Mills-Fenestra Health Services, San Mateo, California, and Centers for Disease Control and Prevention, Atlanta, Georgia.

Abbreviations: (ALF) assisted living facility, (AMBG) assisted monitoring of blood glucose, CDC Centers for Disease Control and Prevention, HCV hepatitis C virus, (SMBG) self-monitoring of blood glucose.

Keywords: assisted monitoring of blood glucose, blood glucose monitoring, diabetes, glucose, hepatitis, monitor, self-monitoring of blood glucose.

Corresponding Author: David C. Klonoff, M.D., FACE, Mills-Fenestra Health Services, 150 South San Mateo Dr., Room M-18, San Mateo, CA 94401; email address: dklonoff@milhsc.org.

### RECOMMENDED PRACTICES FOR PREVENTING BLOODBORNE PATHOGEN TRANSMISSION DURING AMBG IN HEALTH CARE SETTINGS

#### BLOOD GLUCOSE MONITORING

<table>
<thead>
<tr>
<th>Finger-stick devices</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Restrict use of finger-stick devices to individual persons. They should <em>never</em> be used for more than one person. Select single-use lancets that permanently retract upon puncture. This adds an extra layer of safety for the patient and the provider.</td>
</tr>
<tr>
<td>• Dispose of used lancets at the point of use in an approved sharps container. Never reuse lancets.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Blood glucose meters</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Whenever possible, blood glucose meters should be assigned to an individual person and not be shared.</td>
</tr>
<tr>
<td>• If blood glucose meters must be shared, the device should be cleaned and disinfected after every use, per manufacturer’s instructions, to prevent carry-over of blood and infectious agents. If the manufacturer does not specify how the device should be clean and disinfected, then it should not be shared.</td>
</tr>
</tbody>
</table>

Klonoff and Perz J Diab Sci Technol 2010; 4:1027
# RECOMMENDED PRACTICES FOR PREVENTING BLOODBORNE PATHOGEN TRANSMISSION DURING AMBG IN HEALTH CARE SETTINGS

## BLOOD GLUCOSE MONITORING

### Finger-stick devices

- Restrict use of finger-stick devices to individual persons. They should *never* be used for more than one person.

  **Do not share lancets and use retractable single use ones**

- An extra layer of safety for the patient and the provider.

### Blood glucose meters

- Each patient must have their own BGM whenever possible.

  **Shared BGMs: clean/disinfect after each use per mfr’s instructions**

- If blood glucose meters must be shared, the device should be cleaned and disinfected after each use.

- If the manufacturer does not specify how the device should be clean and disinfected, then it should not be shared.

---

Klonoff and Perz J Diab Sci Technol 2010; 4:1027
RECENT REPORTS OF
VIRAL OUTBREAKS
AND RISKY EXPOSURES
DUE TO UNSAFE
AMBG PRACTICES
SAFETY OF SMBG: WHAT ARE THE RISKS?

- Transmission of bloodborne viral pathogens from patient to patient
- Community exposure to sharps and other medical waste
- Finger trauma due to lancing
CURRENTLY IN THE US USED NEEDLES, SYRINGES, AND LANCETS ARE COMMONLY INCERATED OR TREATED AND DISPOSED OF IN LANDFILLS
THE IMPACT OF LANCET, NEEDLE, AND SYRINGE DISPOSAL IN THE US

- 26 M with DM in US; 26% use 1-4 insulin injects/d = 13 M needles & syringes/d
- Lancets and strips are used similarly
- 1 in 12 households in US use a syringe and needle for a medical condition
- Total needle and syringe use in the US is estimated to be 7.5 Billion per year
CDC ADVICE FOR SHARPS DISPOSAL

- Place used sharps in an FDA-cleared sharps disposal container
- Or else a heavy-duty plastic household container: leak-resistant, upright, tight fitting, puncture-resistant lid
- Local trash or Public Health Depts have sharps disposal programs
- No sharps in trash, toilet, or recycling bin
SAFETY OF SMBG: WHAT ARE THE RISKS?

- Transmission of bloodborne viral pathogens from patient to patient
- Community exposure to sharps and other medical waste
- Finger trauma due to lancing
Little published research on safe lancing
AST decreases pain but introduces lag
Laser lancets poorly received and all-in-one devices do not decrease pain
Pain from lancing can be mitigated by optimizing the lancet & lancing process
Controlled lancing can avoid trapped blood (“black dots”) / callus / ↓ sensation
ACCURACY
SETTINGS FOR MEASURING BLOOD GLUCOSE MONITOR PERFORMANCE

- Analytical
- Clinical
- Simulation
SETTINGS FOR MEASURING BLOOD GLUCOSE MONITOR PERFORMANCE

- Analytical
- Clinical
- Simulation
NEW STANDARDS FOR BLOOD GLUCOSE MONITOR ACCURACY

- Revised ISO 15107 ("Requirements for blood glucose monitoring systems for self-testing in managing diabetes mellitus") for outpatient monitors 2003
- FDA Draft Guidances for OTC and Rx POC Blood Glucose Monitors (2014)
MINIMUM ACCURACY CRITERIA FOR BLOOD GLUCOSE MONITORS FROM THE 2003 ISO 15197 STANDARD

95% of glucose results must be:

● For glucose < 75 mg/dl – within 15 mg/dl of reference

● For glucose ≥ 75 mg/dl – within 20% of reference
MINIMUM ACCURACY CRITERIA FOR BLOOD GLUCOSE MONITORS FROM THE 2013 ISO 15197 STANDARD

95% of glucose results must be:
For glucose < 100 mg/dl – within 15 mg/dl of reference
For glucose ≥ 100 mg/dl – within 15 % of reference

99% of glucose results must be:
Within the Parkes (Consensus) Error Grid Zone A or B
Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only. Document issued on: January 7, 2014

You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this document, contact Patricia Bernhardt at patricia.bernhardt@fda.hhs.gov or at 301-796-6136.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of In Vitro Diagnostic Device Evaluation and Radiological Health
Division of Chemistry and Toxicology Devices
Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.
Document issued on: January 7, 2014

You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this document, contact Patricia Bernhardt at patricia.bernhardt@fda.hhs.gov, or at 301-796-6136.

Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use

Draft Guidance for Industry and Food and Drug Administration Staff

DRAFT GUIDANCE

This guidance document is being distributed for comment purposes only.
Document issued on: January 7, 2014

You should submit comments and suggestions regarding this draft document within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.regulations.gov. Identify all comments with the docket number listed in the notice of availability that publishes in the Federal Register.

For questions regarding this document, contact Patricia Bernhardt at patricia.bernhardt@fda.hhs.gov, or at 301-796-6136.

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of In Vitro Diagnostic Device Evaluation and Radiological Health
Division of Chemistry and Toxicology Devices

U.S. Department of Health and Human Services
Food and Drug Administration
Center for Devices and Radiological Health
Office of In Vitro Diagnostic Device Evaluation and Radiological Health
Division of Chemistry and Toxicology Devices
MINIMUM ACCURACY CRITERIA FOR OTC BLOOD GLUCOSE MONITORS FROM THE 2014 DRAFT FDA GUIDANCE

95% of glucose results must be within 15% of reference

99% of glucose results must be within 20% of reference

<table>
<thead>
<tr>
<th>Across the Range</th>
<th>Within +/- 5 mg/dL</th>
<th>Within +/- 7 mg/dL</th>
<th>Within +/- 10 mg/dL</th>
<th>Within +/- 15 mg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>X/Y (%)</td>
<td>X/Y (%)</td>
<td>X/Y (%)</td>
<td>X/Y (%)</td>
<td>X/Y (%)</td>
</tr>
</tbody>
</table>
99% of glucose results must be:
For glucose < 70 mg/dl – within 7 mg/dl of reference
For Glucose ≥ 70 mg/dl – within 10% of reference

And 100% of glucose results must be:
For glucose < 75 mg/dl – within 15 mg/dl of reference
For Glucose ≥ 75 mg/dl – within 20% of reference
SETTINGS FOR MEASURING BLOOD GLUCOSE MONITOR PERFORMANCE

- Analytical
- Clinical
- Simulation
ALL BLOOD GLUCOSE ERRORS OF A PARTICULAR PERCENTAGE FROM THE REFERENCE METHOD DO NOT HAVE EQUAL CLINICAL SIGNIFICANCE
CLARKE ERROR GRID
REPORTED IN 1987

<table>
<thead>
<tr>
<th>Zone</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>No effect on clinical action</td>
</tr>
<tr>
<td>B</td>
<td>No effect on treatment or benign effect on treatment</td>
</tr>
<tr>
<td>C</td>
<td>Altered clinical action likely to affect clinical outcome</td>
</tr>
<tr>
<td>D</td>
<td>Altered clinical action – could have significant medical risk</td>
</tr>
<tr>
<td>E</td>
<td>Altered clinical action – could have dangerous consequences</td>
</tr>
</tbody>
</table>

Clarke D Care 1987; 10:622
PARKES CONSENSUS ERROR GRID DEVELOPED IN 1994 FOR T1DM AND T2DM
LIMITATIONS OF THE TWO ERROR GRIDS THAT ARE WIDELY USED CURRENTLY

- Diabetes management has changed since 1987 (Clarke) and 1994 (Parkes)
- DCCT results were one year old when the more modern ERG was developed
- Analog insulin was unavailable when the EGs were developed
- Analytical accuracy standards used to be looser when the EGs were developed
SETTINGS FOR MEASURING BLOOD GLUCOSE MONITOR PERFORMANCE

• Analytical
• Clinical
• Simulation
Impact of Blood Glucose Self-Monitoring Errors on Glucose Variability, Risk for Hypoglycemia, and Average Glucose Control in Type 1 Diabetes: An In Silico Study

Marc D. Breton, Ph.D., and Boris P. Kovatchev, Ph.D.

Abstract

Background:
Clinical trials assessing the impact of errors in self-monitoring of blood glucose (SMBG) on the quality of glycemic control in diabetes are inherently difficult to execute. Consequently, the objectives of this study were to employ realistic computer simulation based on a validated model of the human metabolic system and to provide potentially valuable information about the relationships among SMBG errors, risk for hypoglycemia, glycemic variability, and long-term glycemic control.

Methods:
Sixteen thousand computer simulation trials were conducted using 100 simulated adults with type 1 diabetes. Each simulated subject was used in four simulation experiments aiming to assess the impact of SMBG errors on detection of hypoglycemia (experiment 1), risk for hypoglycemia (experiment 2), glycose variability (experiment 3), and long-term average glucose control, i.e., estimated hemoglobin A1c (HbA1c)(experiment 4). Each experiment was repeated 10 times at each of four increasing levels of SMBG errors: 5, 10, 15, and 20% deviation from the true blood glucose value.

Results:
When the permitted SMBG error increased from 0 to 5-10% to 15-20%—the current level allowed by International Organization for Standardization 15197—(1) the probability for missing blood glucose readings of 60 mg/dl increased from 0 to 0-1% to 3.5-10%; (2) the incidence of hypoglycemia, defined as reference blood glucose ≤70 mg/dl, changed from 0 to 0-0% to 0.1-5.5%; (3) glycose variability increased as well, as indicated by control variability grid analysis; and (4) the incidence of hypoglycemia increased from 15.0 to 15.2-18.8% to 22-25.6%. When compensating for this increase, glycemic control deteriorated with HbA1c increasing gradually from 7.00 to 7.01-7.12% to 7.26-7.40%.

Conclusions:
A number of parameters of glycemic control deteriorated substantially with the increase of permitted SMBG errors, as revealed by a series of computer simulations (e.g., in silico) experiments. A threshold effect apparent between 10 and 15% permitted SMBG error for most parameters, except for HbA1c, which appeared to be increasing relatively linearly with increasing SMBG error above 15%.

J Diabetes Sci Technol 2010;4(3):562-570
Impact of Blood Glucose Self-Monitoring Errors on Glucose Variability, Risk for Hypoglycemia, and Average Glucose Control in Type 1 Diabetes: An In Silico Study

Marc D. Breton, Ph.D., and Boris P. Kovatchev, Ph.D.
SOURCES OF ERROR IN BLOOD GLUCOSE MONITORING
FACTORS WHICH ADVERSELY AFFECT PERFORMANCE OF BG MONITORS

- Preanalytical – related to specimen procurement and handling prior to performing the measurement
- Analytical – related to performance of the measurement
- Postanalytical – related to how data is delivered, interpreted, and acted upon
OBTAINING A BLOOD GLUCOSE MONITOR TEST RESULT IS LIKE ORDERING A PIZZA
PREANALYTICAL FACTORS WHICH ADVERSELY AFFECT BG MONITORING

- Patient performance (e.g. hand washing, site selection, proper lancing, sampling a hanging drop etc.)
- Strip factors (use past expiration date, exposure to heat and humidity, product imprecision due to lot-to-lot variability)
ANALYTICAL FACTORS WHICH ADVERSELY AFFECT BG MONITORING

- Physical environment (high altitude, heat, cold – if vasoconstriction occurs)
- Physiology ($O_2$, TG, galactose, uric acid, hematocrit)
- Medications (acetaminophen, C, L-dopa, tolazamide, icodextrin/maltose, D-xylose)
- System (strip/parts quality, outlier data)
- Patient performance (following all mfrs instructions, cleaning meter, strip filling)
ANALYTICAL FACTORS WHICH ADVERSELY AFFECT BG MONITORING

- Physical environment
- Physiology
- Medications

ENVIRONMENTAL, PHYSIOLOGICAL, AND PHARMACOLOGICAL FACTORS WHICH AFFECT BG MONITOR PERFORMANCE ARE KNOWN AS INTERFERING SUBSTANCES
POSTANALYTICAL FACTORS WHICH ADVERSELY AFFECT BG MONITORING

- Incorrect units of glucose are presented
- Data is not recorded or uploaded
- Data is transmitted incorrectly
- A misleading message is presented
- Monitor shuts off if BG is very high
AND NOW A WORD ABOUT GLYCEMIC VARIABILITY
THE SIGNIFICANCE AND MEASUREMENT OF GLYCEMIC VARIABILITY

- Patients with the same A1C can have different patterns of fluctuations
- GV provides an integrated picture of PP-hypers and episodes of hypos
- GV triggers endothelial dysfunction and promotes oxidative stress, but the link to clinical outcomes is unproven
- Aim for SD to be $< 0.5 \times $ mean [BG]
CLINICAL INDICATIONS
CURRENT STATUS OF SMBG AS AN INTERVENTION TO IMPROVE OUTCOMES

- A tool for patients which empowers improved day-to-day self-care
- Established to improve BG control in T1DM and insulin-treated T2DM
- Proper use in non-insulin Rx’d T2DM is evolving with use of structured protocols
- Works best when patients and MDs use the information to make Rx decisions
THE OLDER MEDICAL LITERATURE PRIOR TO 2008
MOST OLDER TRIALS OF SMBG IN NIT T2DM HAVE HAD LITTLE VALUE BECAUSE OF SERIOUS METHOD FLAWS

- Not randomized or poorly randomized
- Low baseline A1C
- Intervention subjects did not necessarily practice any study intervention
- Study intervention did not include a structured educational program and a therapeutic response to the BG data
THE NEWER MEDICAL LITERATURE SINCE 2008
NEWER TRIALS OF SMBG IN NIT T2DM SINCE 2008 HAVE AVOIDED THE EARLIER METHOD FLAWS

- Randomized or even cluster randomized
- Sufficiently high baseline A1C
- Intervention subjects have practiced the study SMBG intervention
- Study interventions have included a structured educational program and a therapeutic response to the BG data
NEWER TRIALS OF SMBG IN NIT T2DM SINCE 2008 HAVE AVOIDED THE EARLIER METHOD FLAWS

- Randomized or even cluster randomized
- Sufficiently high baseline A1C
- Intervention subjects have practiced the study SMBG intervention
- Study interventions have included a structured educational program and a therapeutic response to the BG data
MODERN RCTs OF SMBG IN NIT T2DM HAVE USED STRUCTURED SMBG INTERVENTIONS
TWO QUESTIONS ABOUT HOW TO USE SMBG

WHAT ARE THE APPROPRIATE BLOOD GLUCOSE TARGETS?

HOW CAN TREATMENT BE ADJUSTED TO REACH TARGET BG LEVELS USING SMBG?
WHAT ARE THE APPROPRIATE BLOOD GLUCOSE TARGETS?
BLOOD GLUCOSE GOALS PER MAJOR ORGANIZATION GUIDELINES ARE FASTING 70-130 MG/DL AND AFTER MEALS UP TO 140-180 MG/DL

<table>
<thead>
<tr>
<th></th>
<th>ADA (1)</th>
<th>AACE (2)</th>
<th>IDF-Europe type 1 (3)</th>
<th>IDF type 2 (4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HbA1c, % (mmol/mol)</td>
<td>&lt;7 (&lt;53)</td>
<td>≤6.5 (≤48)</td>
<td>6.2–7.5 (44–58)</td>
<td>&lt;7 (53)</td>
</tr>
<tr>
<td>Premeal, mg/dL</td>
<td>70–130</td>
<td>&lt;110</td>
<td>91–120</td>
<td>&lt;115</td>
</tr>
<tr>
<td>Postmeal, mg/dL</td>
<td>&lt;180</td>
<td>&lt;140</td>
<td>136–160</td>
<td>&lt;160</td>
</tr>
<tr>
<td>Before bedtime, mg/dL</td>
<td></td>
<td></td>
<td>110–135</td>
<td></td>
</tr>
</tbody>
</table>
# Mean Blood Glucose Levels for Bins of Hemoglobin A1c Levels

<table>
<thead>
<tr>
<th>Blood Glucose (mg/dl with 95% CI)</th>
<th>Hemoglobin A1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5.5 - 6.49</td>
<td></td>
</tr>
<tr>
<td>Mean fasting</td>
<td>122 (117-127)</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>118 (115-121)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td>144 (139-148)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>136 (131-141)</td>
</tr>
<tr>
<td>6.5 - 6.99</td>
<td></td>
</tr>
<tr>
<td>Mean fasting</td>
<td>142 (135-150)</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>139 (134-144)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td>164 (159-169)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>153 (145-161)</td>
</tr>
<tr>
<td>7.0 - 7.49</td>
<td></td>
</tr>
<tr>
<td>Mean fasting</td>
<td>152 (143-162)</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>152 (147-157)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td>176 (170-183)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>177 (166-188)</td>
</tr>
<tr>
<td>7.5 - 7.99</td>
<td></td>
</tr>
<tr>
<td>Mean fasting</td>
<td>167 (157-177)</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>155 (148-161)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td>189 (180-197)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>175 (163-188)</td>
</tr>
<tr>
<td>8.0 - 8.5</td>
<td></td>
</tr>
<tr>
<td>Mean fasting</td>
<td>178 (164-192)</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>179 (167-191)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td>206 (195-217)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>222 (197-248)</td>
</tr>
</tbody>
</table>

**Notes:**
- Mean fasting, premeal, postmeal, and bedtime blood glucose levels are given.
- Hemoglobin A1c levels are divided into bins: 5.5 - 6.49%, 6.5 - 6.99%, 7.0 - 7.49%, 7.5 - 7.99%, and 8.0 - 8.5%.
- Each bin has a corresponding mean blood glucose level with its 95% confidence interval (CI) provided in parentheses.
**DIFFERENCE BETWEEN PREMEAL AND POSTMEAL GLUCOSE LEVELS FOR SPECIFIED HBA1C LEVELS**

<table>
<thead>
<tr>
<th>Blood Glucose (mg/dl with 95% CI)</th>
<th>Hemoglobin A1c (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>5.5 - 6.49</td>
</tr>
<tr>
<td>Mean fasting</td>
<td>n = 119</td>
</tr>
<tr>
<td>Mean premeal</td>
<td>122 (117-127)</td>
</tr>
<tr>
<td>Mean postmeal</td>
<td><strong>26</strong> (115-121)</td>
</tr>
<tr>
<td>Mean bedtime</td>
<td>136 (131-141)</td>
</tr>
</tbody>
</table>
HOW CAN TREATMENT BE ADJUSTED TO REACH TARGET BLOOD GLUCOSE LEVELS USING SMBG?
STRUCTURED SMBG INTERVENTION

1) PATIENT MUST PERFORM SMBG AT A FIXED TIME AND FREQUENCY

2) PATIENT OR HEALTHCARE PROFESSIONAL MUST ANALYZE AND RESPOND TO THE BG DATA PATTERN ACCORDING TO A PROTOCOL
1. Structured Testing

2. Pattern Analysis

3. Response per Protocol

Structured Intervention Based on SMBG Data
STRUCTURED INTERVENTION BASED ON SMBG DATA

STRUCTURED TESTING
STRUCTURED INTERVENTION BASED ON SMBG DATA

PATTERN ANALYSIS
PATTERN ANALYSIS APPROACH TO SMBG

EMPHASIS ON BEHAVIOR AND MEDICATIONS

- Identify the glycemic abnormality
- Determine the timing and frequency of occurrence
- Investigate potential causes, including behavior (eating/activity/stress) & meds
- Take action to adjust behavior or meds
RESPONSES PER PROTOCOL
STRUCTURED RESPONSES TO SMBG FOR INSULIN TREATED PATIENTS

- Adjust long acting insulin with a treat-to-target regimen based on fasting BG.
- Adjust out-of-range pre-prandial BG (lunch/dinner/bed) by adjusting the sliding scale dose or the carb:insulin ratio at the preceding meal.
- Adjust out-of-range post-prandial BG by adjusting the sliding scale dose or the carb:insulin ratio at the preceding meal.
THE KAISER PERMANENTE ALGORITHM FOR ADJUSTING MEDICATIONS FOR NIT T2DM USING A PATTERN ANALYSIS APPROACH
FUTURE BARRIERS AND OPPORTUNITIES FOR BLOOD GLUCOSE MONITORING
### FUTURE BARRIERS AND OPPORTUNITIES FOR BLOOD GLUCOSE MONITORING

<table>
<thead>
<tr>
<th>Barriers to BG Monitoring</th>
<th>Opportunities for BG Monitoring</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accuracy of generic monitors?</td>
<td>Advances in Accuracy</td>
</tr>
<tr>
<td>Accuracy of generic strips?</td>
<td>Advances in Human Factors</td>
</tr>
<tr>
<td>Counterfeit Strips</td>
<td>Advances in Data presentation</td>
</tr>
<tr>
<td>Cutbacks in Coverage</td>
<td>Decision Support Software / Mobile applications</td>
</tr>
<tr>
<td>Fixed Pricing and Stifled Innovation</td>
<td>FGS for Better Hypoglycemia Detection</td>
</tr>
</tbody>
</table>
DIAGNOSIS OF ASYMPTOMATIC DIABETES AND PREDIABETES USING A1C, FASTING PLASMA GLUCOSE, AND A 2-HOUR GLUCOSE TOLERANCE TEST TOLERANCE TEST
Safe practices avoid blood transmission, sharps exposure, and finger trauma.

Accuracy can mean analytical, clinical, and modeling performance metrics.

SMBG is for any DM patient, including NIT T2DM patients on structured testing.

Barriers and technology opportunities will clash and determine future of SMBG.

BLOOD GLUCOSE MONITORING: PAST, PRESENT, AND FUTURE

CONCLUSIONS